This study gives proof-of-concept of efficacy, tolerability and clinical relevance of the combined gene/cell therapies proposed here, which may constitute a feasible and effective therapeutic opportunity for children affected by GLD.
These results give proof-of-concept that progenitor cell types can be produced in sufficient quantities for use in canine therapeutic cell transplantation for SCI in veterinary medicine.
We have given proof-of-concept for this new approach with mimotope A12.2 and have brought the finding full-circle by demonstrating differential recognition of native versus denatured HIV-C gp160 by phage affinity-purified rhesus monkey abs.
Together, in vitro and in vivo data give proof of concept of higher therapeutic activity of tumor-targeted scFv scTRAIL molecules.
(#1020, 56, W) Besides giving additional support to the findings of the first (hypothetical) stage of our study, the results reported here give proof of concept that HIV-uninfected MSM from diverse ethnic backgrounds who never or rarely use condoms and have intercourse with multiple partners understand the limitations of HT and are willing and able to use HT to screen partners.
The present proof-of-concept study gives efficacy and safety arguments warranting the further clinical evaluation of the H-1PV/VPA combination for use against life-threatening cancers.
The analysis of gene and miRNAs expression profiles gave a proof-of-concept of the scalable character of biological regulation circuits.
By analyzing both protein coding genes (PCGs) and miRNAs expression during hematopoiesis, we gave a proof-of-concept of this attractor-like dynamics and were able to characterize the coordinated and scalable character of cell population behaviour in both mRNAs and miRNAs spaces.
This further gives a proof of concept of our hypothesis that delay in repression is the primary factor for inducing increased inter-cellular heterogeneity in gene expression in a population.
However, evolutionary examples of enzyme recruitment in the vertebrate eye lens or the evolution of antifreeze proteins have already given the proof of concept that novel functions can evolve from seemingly inappropriate genes.
The good performance of first solar cell devices with a maximum efficiency of 7.5% gives a solid proof-of-concept for ceramic solar tiles based on efficient kesterite absorbers.
